Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemiaFedorenko, O. Y., Paderina, D. Z., Loonen, A. J. M., Pozhidaev, I., Boiko, A. S., Kornetova, E. G., Bokhan, N. A., Wilffert, B. & Ivanova, S. A., 8-May-2020, In : Human Psychopharmacology. 35, 4, 8 p., 2737.
Research output: Contribution to journal › Article › Academic › peer-review
Objective: Schizophrenia is a severe highly heritable mental disorder. Genetic polymorphisms of dopaminergic pathways are related to pathogenesis of drug response. Hyperprolactinemia (HPRL), a common adverse effect of antipsychotics, is attributed to blockade of dopamine D2 receptors. Ankyrin Repeat and Kinase Domain containing 1 (ANKK1) gene is closely related to Dopamine Receptor D2 type (DRD2) gene functioning. We examined whether the functional polymorphism rs2734849 in the ANKK1 gene is associated with antipsychotic-induced HPRL. Methods: We recruited 446 patients with schizophrenia from among the Russian population of the Siberian region. The polymorphism rs2734849 in the ANKK1 gene was genotyped with The MassARRAY® Analyzer 4 by Agena Bioscience™, using the kit SEQUENOM Consumables iPLEXGold 384. Genotype and allele frequencies were compared between groups of schizophrenia patients with and without HPRL using the χ2 test. Results: A comparison between schizophrenia patients with and without HPRL revealed significantly higher frequency of the C allele of the polymorphic variant rs2734849 in the ANKK1 gene in patients with HPRL as compared to the patients without it (χ2 = 3.70; p =.05; odds ratio [OR] = 1.30 [0.99–1.69]). Conclusion: The functional polymorphism rs2734849 in the ANKK1 gene was associated with HPRL in patients with schizophrenia.
|Number of pages||8|
|Publication status||Published - 8-May-2020|
- ANKK1, hyperprolactinemia, polymorphism, schizophrenia, D2 RECEPTOR-BINDING, KINASE GENE, SCHIZOPHRENIA, DRD2, IDENTIFICATION, ACTIVATION, REGION, SUSCEPTIBILITY, REPEAT, CYP2D6